Testing Rilzabrutinib with Glucocorticoid against a placebo for immunoglobulin G4 related disease

Exclusion

• −Meet any Step 2 Exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → from the 2019 ACR/EULAR classification criteria for IgG4-RD.
• −History of retroperitoneal fibrosis, sclerosing mesenteritis, fibrosing mediastinitis, or other overwhelmingly fibrotic expression of IgG4-RD that is the sole disease manifestation.
• −Active malignancy or history of malignancy within 5 years before Day 1, except completely treated in situ carcinoma of the cervix, completely treated, and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
• −Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →.
• −History of serious infections with the potential for recurrence (as judged by the Investigator), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at ScreeningScreeningThe checks done before joining, to see whether a study fits.Read more → (Grade 2 or higher).
• −Current or chronic history of liver disease unrelated to IgG4-RD.
• −History of solid organ transplant.
• −Planned major surgical procedure during the participation in this study.
• −History of drug abuse within the previous 12 months.
• −Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day.
• −Prior participation in any rilzabrutinib studies or other BTK inhibitor studies.
• −History of treatment with an investigational drug within 6 months or 5 half-lives of the investigational drug, whichever is longer.
• −Laboratory abnormalities at the screening visit identified by the central laboratory The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trialInterventional studyA study where participants are given something to see what happens.Read more →.
• −Refractory nausea and vomiting, malabsorption, external biliary shunt, bariatric surgery, or significant bowel resection that would preclude adequate rilzabrutinib/placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → absorption.